Greetje J. Tack

Greetje J. Tack

Auto-generated profile, based on publicly available information

Greetje J. Tack

Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2010 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
GTGreetje J. Tack
Greetje J. Tack
WVWieke H. M. Verbeek
Wieke H. M. Verbeek
MSMarco W. J. Schreurs
Marco W. J. Schreurs
CMChris J. J. Mulder
Chris J. J. Mulder

1 January 2013 in World Journal of Gastroenterology
Verified
Journal Article
Open access
GTGreetje J Tack
Greetje J Tack
JWJolanda M W Van De Water
Jolanda M W Van De Water
MBMaaike J Bruins
Maaike J Bruins
EKEngelina M C Kooy-Winkelaar
Engelina M C Kooy-Winkelaar
JBJeroen Van Bergen
Jeroen Van Bergen
FKFrits Koning
Frits Koning
To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN-PEP) to mitigate the immunogenic effects of gluten in celiac patients. Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included. In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase). After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase). Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology. Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase. Duodenal biopsies were collected after the safety phase and after the efficacy phase. A change in histological evaluation according to the modified Marsh classification was the primary endpoint. In total, 16 adults were enrolled in the study. No serious adverse events occurred during the trial and no patients withdrew during the trial. The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated. In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed. During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers. The IgA-EM concentrations remained negative in both groups. Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP. Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP. Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo. In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits. AN-PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN-PEP.

1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
GTGreetje J Tack
Greetje J Tack
WVWieke H M Verbeek
Wieke H M Verbeek
AAAbdulbaqi Al-Toma
Abdulbaqi Al-Toma
DKDirk J Kuik
Dirk J Kuik
MSMarco W J Schreurs
Marco W J Schreurs
CMChris J J Mulder
Chris J J Mulder
To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) II. An open-label cohort-study of RCD II patients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates were evaluated. Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. Treatment of RCD II with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL.

6 September 2010 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
GTG J Tack
G J Tack
MWM J Wondergem
M J Wondergem
AAAbdulbaqi Al-Toma
Abdulbaqi Al-Toma
WVW H M Verbeek
W H M Verbeek
ASA Schmittel
A Schmittel
OVO J Visser
O J Visser

1 April 2012 in Molecular Immunology
Verified
Journal Article
Closed access
GTGreetje J. Tack
Greetje J. Tack
RWRoy L.J. van Wanrooij
Roy L.J. van Wanrooij
ALAnton W. Langerak
Anton W. Langerak
JTJennifer Tjon
Jennifer Tjon
BBB. Mary E. von Blomberg
B. Mary E. von Blomberg
MSMarco W.J. Schreurs
Marco W.J. Schreurs

30 May 2012 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
GTG. J. Tack
G. J. Tack
DAD. P. van Asseldonk
D. P. van Asseldonk
RWR. L. J. van Wanrooij
R. L. J. van Wanrooij
ABA. A. van Bodegraven
A. A. van Bodegraven
CMC. J. Mulder
C. J. Mulder